Dihexa 1401708-83-5 High Purity Peptide Powder with factory wholesale
TDS 180 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
China
Runlian or as clients' requirement
box
2027-12-30
peptide
-
Product Details
-
Seller Information
-
History Price
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
Certificates-
TDS
Basic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptide
-
Location:
Room A0693, 6th Floor, Building 3, No.5 Lvtai Road, Zhongtai Subdistrict, Yuhang District, Hangzhou City, Zhejiang Province
-
Average lead Time:
15 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
51-100
-
Year of Establishment:
2025
Company Certificates-
TR60 COA
-
-
Weekly Price
The chart shows the price trend of the product in the past 12 months.
-
Inquiry History180 Inquiries
Country Product Purchase Quantity Date Posted
United States
Dihexa
1 KG Oct 26, 2026
Thailand
Dihexa
1 G Oct 23, 2026
Australia
Dihexa
30 G Oct 19, 2026
Australia
Dihexa
2 G Oct 19, 2026
United States
Dihexa
100 PCS Oct 15, 2026
United States
Multi-Product Research Chemical Bulk Sourcing Inquiry
2.6 KG Oct 8, 2026
Philippines
Dihexa
1 KG Oct 2, 2026
United States
dihexa
10 MG Sep 28, 2026
Australia
Dihexa
1 MT Sep 18, 2026
United States
Dihexa
10 G Sep 9, 2026
Hungary
Dihexa
1 G Sep 7, 2026
India
Dihexa
10 MG Sep 4, 2026
Spain
Dihexa
100 MG Aug 30, 2026
Spain
Dihexa
50 MG Aug 28, 2026
United Arab Emirates
Diheza
1 G Aug 28, 2026
Norway
Dihexa
1 G Aug 26, 2026
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
SHLP2 ; PE-22-28; Dihexa ; TAK-653 ; lyophilized
10 PCS Aug 23, 2026
United States
Dihexa
1 G Aug 22, 2026
United States
Dihexa
500 G Aug 19, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Supply raw FOXO4-DRI powder CAS 2460055-10-9 and FOXO4-DRI best price
Pharmaceutical Grade / 99%
$32-33/BOU FOB
-
-
-
-
Cardiogen 857267-11-9 | China Factory | Cosmetic Peptides | 99% Purity | Lyophilized Powder | hign quality
Pharmaceutical Grade / 99%
$12-13/BOU FOB
-
-
-
-
Botulinum Toxin | CAS 93384-43-1 | 99% Purity Research & Cosmetic Grade Raw Powder
Pharmaceutical Grade / 99%
$9-10/BOU FOB
-
-
-
-
LL37 Peptide with High quality wholesales peptides 154947-66-7 with high quatity
Pharmaceutical Grade / 99%
$12-13/BOU FOB
-
-
-
-
Cosmetic Peptides Matrixyl Synthe6/Palmitoyl Tripeptide-38 /Palmitoyl Tripeptide 38 CAS 1447824-23-8
Pharmaceutical Grade / 99%
$5/G FOB
-
-
-
-
Selank 5mg 10mg Wholesale Price High Quality Peptides 99% Peptide powder SK5 SK10
Pharmaceutical Grade / 99%
$3.5-4/BOU FOB
-

